Omicron-specific Sinopharm COVID-19 vaccine approved for clinical trials in China

2022-04-26 06:44:25

Omicron-specific Sinopharm COVID-19 vaccine candidate.

Asian Tech Press (Apr. 26) -- Sinopharm's COVID-19 vaccine candidate against Omicron variant got approval for clinical trials in China.

China National Biotec Group Co., Ltd. (CNBG), a subsidiary of Chinese state-owned drugmaker Sinopharm Group Co. Ltd., announced Tuesday its Omicron-specific COVID-19 vaccine candidate has received approval from the National Medical Products Administration (NMPA) for clinical trials.

CNBG will conduct clinical trials on sequential Immunization of the new vaccine candidate, using a randomized, double-blind, cohort study to evaluate the safety and immunogenicity of an inactivated vaccine against Omicron variant in a population aged 18 years and older who have completed two or three doses of COVID-19 vaccination.

China vaccine COVID-19 vaccine Omicron variant Sinopharm

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Tencent Holdings repurchased 3.93 million shares for HK$1.5 billion on January 7
                            2025-01-07

                                    Ireland recorded a 12.8 billion euro fiscal surplus last year due to the "Apple tax" ruling
                            2025-01-07

                                    Ministry of Industry and Information Technology: Promoting technical verification of 10G optical network and artificial intelligence integration
                            2025-01-07

                                    Tencent's major shareholder Prosus reduced its stake in Tencent Holdings from 24.01% to 23.99% on January 6.
                            2025-01-07

                                    U.S. chip stocks rose before the market opened, with Nvidia up 0.6%
                            2025-01-07